DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)
Jupid | $840,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
Certified by Founder
Lodge
Remedy Plan Therapeutics
start up
United States
- Gaithersburg, MD
- 14/05/2025
- Unknown
- $18,000,000
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedy’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Remedy's lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024.
- Industry Biotechnology
- Website https://remedyplan.com/
- LinkedIn https://www.linkedin.com/company/remedy-plan/
Creati AI | $20,000,000 | (May 1, 2026)
Manifest OS | $60,000,000 | (May 1, 2026)
Iterative Health | $77,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Illuminant Surgical | $8,400,000 | (May 1, 2026)
BioOrbit | $13,334,811 | (May 1, 2026)
Parallel Web Systems | $100,000,000 | (Apr 30, 2026)
Fence | $20,000,000 | (Apr 30, 2026)
Certifyde | $2,000,000 | (Apr 30, 2026)